The company would continue to focus on R&D for some interesting pipeline of proprietary products.
Narnolia Financial Advisors expects the pharma company to report a net profit of Rs 545 crore as against Rs 500 crore in the last quarter
The company has launched its product, which is generic version of Merck Sharp & Dohme Corp's Cubicin, after obtaining approval from the US Food and Drug Administration (USFDA), the Hyderabad-based firm said in a statement.
The company's testosterone gel 1.62 percent is a therapeutic equivalent generic version of AndroGel 1.62 percent of AbbVie Inc.
Dr Reddy's Laboratories Inc, a subsidiary of the Hyderabad-based Dr Reddy's Laboratories, is voluntarily recalling the affected lot of bottles on account of certain deviations from the Current Good Manufacturing Practice (CGMP) regulations.
Clopidogrel is an anti-platelet drug that blocks platelets from sticking together and prevents them from forming harmful clots.
Net Sales are expected to increase by 7.7 percent Y-o-Y (down 1.1 percent Q-o-Q) to Rs. 3,807.5 crore, according to Kotak.
Japanese brokerage house Nomura said the deal is positive both from a strategic as well as a financial perspective.
The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets, Dr Reddy's Laboratories CEO Erez Israeli said.
Net Sales are expected to increase by 12.4 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 3,994.3 crore, according to Prabhudas Lilladher.
REVLIMID (Lenalidomide) is indicated for treatment for multiple myeloma (cancer).
"Dr Reddy's Tadalafil tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size," Dr Reddy's Laboratories said in a BSE filing.
In a regulatory filing Dr Reddy's said, "The audit of our formulations Shreveport plant, Louisiana, USA, by the United States Food and Drug Administration (USFDA) has been completed with zero observations".
According to the latest Enforcement Report of the USFDA, the drug firm is recalling Levetiracetam in 0.54 percent Sodium Chloride injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags.
Volatility in Dr Reddy's has shot up due to news flows. An Iron Condor trade to cash in on falling volatility going forward.
Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, is a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, Dr Reddy's said in a BSE filing.
Dr Reddy’s generic Suboxone launch is set to be a reality. A much-awaited event, a mounting threat from competitors may limit its benefits
ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 2870 in its research report dated February 04, 2019.
Majority of brokerage houses turned positive on the stock, advising buying after the USFDA issued EIR for Duvvada facility.
This Duvvada facility in Andhra Pradesh was included in the warning letter received from USFDA in November 2015
Quoting IMS Health data, Dr Reddy's Laboratories said, the Adcirca brand and generic had US sales of approximately USD 490 million for the most recent twelve months ending in November 2018.
Of the 34 Nifty companies that have announced their earnings, 25 have either met or exceeded consensus estimates on both the PAT and EBITDA front
The drug firm said it denies any wrongdoing and intends to vigorously defend against these claims.